Product
Recombinant Anti-IL-1β
1 clinical trial
1 indication
Indication
Gout ArthritisClinical trial
A Randomized, Open-label, Active-Controlled Phase II Trial to Evaluate the Efficacy and Safety of SSGJ-613 for Prophylaxis Against Acute Gouty Arthritis Flares in Subjects Initiating Urate-Lowering Treatment.Status: Recruiting, Estimated PCD: 2024-06-01